Moderna Inc. (Nasdaq: MRNA) announced results from in vitro neutralization studies of sera from individuals vaccinated with the Moderna COVID-19 vaccine showing activity against emerging strains of SARS-CoV-2. Vaccination with the Moderna COVID-19 vaccine produced neutralizing titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the U.K. and Republic of South Africa.
The two-dose regimen of the Moderna COVID-19 vaccine at the 100 µg dose is expected to be protective against emerging strains detected to date. That said, their clinical strategy to proactively address the pandemic continues to evolve. The company will test an additional booster dose of its COVID-19 Vaccine (mRNA-1273) to study the ability to further increase neutralizing titers against emerging strains beyond the existing primary vaccination series. The company is also advancing an emerging variant booster candidate (mRNA-1273.351) against the B.1.351 variant first identified in the Republic of South Africa.
Whether you receive the Moderna vaccine, the Pfizer vaccine, or any other vaccine to protect you against COVID-19, know that the science is still evolving. These vaccine companies haven’t stepped back and enjoyed the success; they continue to work at preventing the next virus strain from spreading.
Stay the course, stay well, mask up, get vaccinated, and stay tuned!